![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: TTLL5 |
Gene summary for TTLL5 |
![]() |
Gene information | Species | Human | Gene symbol | TTLL5 | Gene ID | 23093 |
Gene name | tubulin tyrosine ligase like 5 | |
Gene Alias | CORD19 | |
Cytomap | 14q24.3 | |
Gene Type | protein-coding | GO ID | GO:0000226 | UniProtAcc | Q6EMB2 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
23093 | TTLL5 | CCI_1 | Human | Cervix | CC | 5.12e-09 | 9.34e-01 | 0.528 |
23093 | TTLL5 | CCI_2 | Human | Cervix | CC | 2.81e-06 | 7.17e-01 | 0.5249 |
23093 | TTLL5 | CCI_3 | Human | Cervix | CC | 1.98e-06 | 6.27e-01 | 0.516 |
23093 | TTLL5 | HTA11_2487_2000001011 | Human | Colorectum | SER | 4.96e-02 | -3.04e-01 | -0.1808 |
23093 | TTLL5 | HTA11_7696_3000711011 | Human | Colorectum | AD | 5.12e-03 | -2.59e-01 | 0.0674 |
23093 | TTLL5 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 5.30e-05 | -3.62e-01 | 0.3859 |
23093 | TTLL5 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 2.17e-09 | -4.27e-01 | 0.3005 |
23093 | TTLL5 | A015-C-203 | Human | Colorectum | FAP | 2.46e-23 | -4.17e-01 | -0.1294 |
23093 | TTLL5 | A015-C-204 | Human | Colorectum | FAP | 3.98e-07 | -4.59e-01 | -0.0228 |
23093 | TTLL5 | A002-C-201 | Human | Colorectum | FAP | 1.99e-10 | -3.07e-01 | 0.0324 |
23093 | TTLL5 | A001-C-119 | Human | Colorectum | FAP | 2.46e-03 | -3.36e-01 | -0.1557 |
23093 | TTLL5 | A001-C-108 | Human | Colorectum | FAP | 3.71e-09 | -2.83e-01 | -0.0272 |
23093 | TTLL5 | A002-C-205 | Human | Colorectum | FAP | 7.58e-16 | -3.51e-01 | -0.1236 |
23093 | TTLL5 | A015-C-005 | Human | Colorectum | FAP | 2.67e-03 | -2.57e-01 | -0.0336 |
23093 | TTLL5 | A015-C-006 | Human | Colorectum | FAP | 1.91e-12 | -3.29e-01 | -0.0994 |
23093 | TTLL5 | A015-C-106 | Human | Colorectum | FAP | 6.25e-09 | -3.04e-01 | -0.0511 |
23093 | TTLL5 | A002-C-114 | Human | Colorectum | FAP | 5.41e-16 | -4.53e-01 | -0.1561 |
23093 | TTLL5 | A015-C-104 | Human | Colorectum | FAP | 1.02e-23 | -4.49e-01 | -0.1899 |
23093 | TTLL5 | A001-C-014 | Human | Colorectum | FAP | 2.52e-06 | -2.62e-01 | 0.0135 |
23093 | TTLL5 | A002-C-016 | Human | Colorectum | FAP | 6.48e-16 | -3.13e-01 | 0.0521 |
Page: 1 2 3 4 5 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Breast | Precancer | ![]() |
Breast | IDC | ![]() |
Breast | DCIS | ![]() |
Cervix | CC | ![]() |
Cervix | HSIL_HPV | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0150063 | Cervix | CC | visual system development | 63/2311 | 375/18723 | 6.58e-03 | 3.65e-02 | 63 |
GO:0001654 | Cervix | CC | eye development | 62/2311 | 371/18723 | 7.83e-03 | 4.13e-02 | 62 |
GO:0048880 | Cervix | CC | sensory system development | 63/2311 | 381/18723 | 9.29e-03 | 4.66e-02 | 63 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TTLL5 | SNV | Missense_Mutation | c.211N>G | p.Arg71Gly | p.R71G | Q6EMB2 | protein_coding | deleterious(0) | possibly_damaging(0.903) | TCGA-A2-A0EQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
TTLL5 | SNV | Missense_Mutation | rs374783896 | c.568N>A | p.Val190Ile | p.V190I | Q6EMB2 | protein_coding | tolerated(0.91) | benign(0.188) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TTLL5 | SNV | Missense_Mutation | novel | c.2430N>T | p.Lys810Asn | p.K810N | Q6EMB2 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TTLL5 | SNV | Missense_Mutation | rs746432496 | c.1033N>G | p.Ser345Gly | p.S345G | Q6EMB2 | protein_coding | deleterious(0) | possibly_damaging(0.796) | TCGA-AR-A24R-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD |
TTLL5 | SNV | Missense_Mutation | c.2747C>T | p.Ser916Phe | p.S916F | Q6EMB2 | protein_coding | deleterious(0.02) | benign(0.224) | TCGA-B6-A0WZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
TTLL5 | SNV | Missense_Mutation | c.1723G>A | p.Ala575Thr | p.A575T | Q6EMB2 | protein_coding | tolerated(0.69) | benign(0.007) | TCGA-BH-A0DS-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cyclophosphamide | SD | |
TTLL5 | insertion | In_Frame_Ins | novel | c.1604_1605insTATACT | p.Ala535_Lys536insIleLeu | p.A535_K536insIL | Q6EMB2 | protein_coding | TCGA-A8-A07G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | CR | ||
TTLL5 | insertion | Nonsense_Mutation | novel | c.1606_1607insGAGACTGAAAACTCCCAGAGGAGTTAGGATG | p.Lys536ArgfsTer3 | p.K536Rfs*3 | Q6EMB2 | protein_coding | TCGA-A8-A07G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | CR | ||
TTLL5 | insertion | Frame_Shift_Ins | novel | c.554_555insTTCTTTG | p.Arg186SerfsTer29 | p.R186Sfs*29 | Q6EMB2 | protein_coding | TCGA-AN-A03X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
TTLL5 | insertion | Nonsense_Mutation | novel | c.555_556insGGGTAGAGATATCGCATATCTTTGGATGTT | p.Ser185_Arg186insGlyTerArgTyrArgIleSerLeuAspVal | p.S185_R186insG*RYRISLDV | Q6EMB2 | protein_coding | TCGA-AN-A03X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |